Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes

A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2000-12, Vol.86 (12), p.42-47
1. Verfasser: Boden, William E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 47
container_issue 12
container_start_page 42
container_title The American journal of cardiology
container_volume 86
creator Boden, William E
description A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-driven process. An early routine invasive or “drive-through” strategy, which consists of cardiac catheterization followed by percutaneous coronary intervention within 24 hours of the onset of angina, has not been shown to result in improved outcomes. In fact, investigators in the Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) trial found that aggressively treated patients had significantly worse outcomes during the first year of follow-up than did those treated with a conservative strategy. In this overview, a conservative (ischemia-guided) strategy with aggressive medical therapy is recommended for patients with non–ST-segment elevation acute coronary syndrome. This conservative treatment includes intensive antiplatelet, antithrombotic, and anti-ischemic therapy combined with careful clinical assessment and provocative testing. Patients undergo catheterization and revascularization only if spontaneous angina occurs or there is objective evidence of stress-induced myocardial ischemia. In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk. Tailoring therapy to the level of risk is essential to optimizing efficacy and clinical outcomes.
doi_str_mv 10.1016/S0002-9149(00)01480-6
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72544871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914900014806</els_id><sourcerecordid>72544871</sourcerecordid><originalsourceid>FETCH-LOGICAL-e318t-df09335e188ecf4d13f26d202345a6d13978580b770449577b157cb8c07b92953</originalsourceid><addsrcrecordid>eNpdkU1vFDEMhiMEotvCTwBFICE4DNiTySRzqqqqfEiVOLSco2zG06aaSZZkZlHhz5PdLj1wsi0_tuz3ZewVwkcEbD9dAUBdddh07wE-ADYaqvYJW6FWXYUdiqds9YgcseOc70qJKNvn7AixhhZQr9ifs230vQ2OeBx4isvsA_FEW5vdMtrkf9vZx8B94PMt8ckGe0MThXmHb0qvpJn_8vMtDzFUV9dVppt9n8ayZD9r3TITdzHFYNM9z_ehT3Gi_II9G-yY6eUhnrAfny-uz79Wl9-_fDs_u6xIoJ6rfoBOCEmoNbmh6VEMddvXUItG2raUndJSw1opaJpOKrVGqdxaO1Drru6kOGHvHvZuUvy5UJ7N5LOjcbSB4pKNqmXTaIUFfPMfeBeXFMptphYgZFu3TYFeH6BlPVFvNslP5S3zT9MCvD0ARUM7Dqmo6_Mjp5WUYkedPlBUPt96Sia7Iqaj3idys-mjNwhm57XZe212RhoAs_fatOIvUqaauA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230356264</pqid></control><display><type>article</type><title>Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Boden, William E</creator><creatorcontrib>Boden, William E</creatorcontrib><description>A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-driven process. An early routine invasive or “drive-through” strategy, which consists of cardiac catheterization followed by percutaneous coronary intervention within 24 hours of the onset of angina, has not been shown to result in improved outcomes. In fact, investigators in the Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) trial found that aggressively treated patients had significantly worse outcomes during the first year of follow-up than did those treated with a conservative strategy. In this overview, a conservative (ischemia-guided) strategy with aggressive medical therapy is recommended for patients with non–ST-segment elevation acute coronary syndrome. This conservative treatment includes intensive antiplatelet, antithrombotic, and anti-ischemic therapy combined with careful clinical assessment and provocative testing. Patients undergo catheterization and revascularization only if spontaneous angina occurs or there is objective evidence of stress-induced myocardial ischemia. In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk. Tailoring therapy to the level of risk is essential to optimizing efficacy and clinical outcomes.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/S0002-9149(00)01480-6</identifier><identifier>PMID: 11206018</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Angina pectoris ; Angina, Unstable - drug therapy ; Angina, Unstable - mortality ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Cardiology ; Clinical outcomes ; Health risk assessment ; Humans ; Medical sciences ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Risk Assessment ; Survival Analysis ; Syndrome ; Therapy ; Thrombolytic Therapy ; Treatment Outcome</subject><ispartof>The American journal of cardiology, 2000-12, Vol.86 (12), p.42-47</ispartof><rights>2000 Excerpta Medica Inc.</rights><rights>2001 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Dec 28, 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9149(00)01480-6$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,777,781,786,787,3537,23911,23912,25121,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=875538$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11206018$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boden, William E</creatorcontrib><title>Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-driven process. An early routine invasive or “drive-through” strategy, which consists of cardiac catheterization followed by percutaneous coronary intervention within 24 hours of the onset of angina, has not been shown to result in improved outcomes. In fact, investigators in the Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) trial found that aggressively treated patients had significantly worse outcomes during the first year of follow-up than did those treated with a conservative strategy. In this overview, a conservative (ischemia-guided) strategy with aggressive medical therapy is recommended for patients with non–ST-segment elevation acute coronary syndrome. This conservative treatment includes intensive antiplatelet, antithrombotic, and anti-ischemic therapy combined with careful clinical assessment and provocative testing. Patients undergo catheterization and revascularization only if spontaneous angina occurs or there is objective evidence of stress-induced myocardial ischemia. In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk. Tailoring therapy to the level of risk is essential to optimizing efficacy and clinical outcomes.</description><subject>Angina pectoris</subject><subject>Angina, Unstable - drug therapy</subject><subject>Angina, Unstable - mortality</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Cardiology</subject><subject>Clinical outcomes</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Assessment</subject><subject>Survival Analysis</subject><subject>Syndrome</subject><subject>Therapy</subject><subject>Thrombolytic Therapy</subject><subject>Treatment Outcome</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1vFDEMhiMEotvCTwBFICE4DNiTySRzqqqqfEiVOLSco2zG06aaSZZkZlHhz5PdLj1wsi0_tuz3ZewVwkcEbD9dAUBdddh07wE-ADYaqvYJW6FWXYUdiqds9YgcseOc70qJKNvn7AixhhZQr9ifs230vQ2OeBx4isvsA_FEW5vdMtrkf9vZx8B94PMt8ckGe0MThXmHb0qvpJn_8vMtDzFUV9dVppt9n8ayZD9r3TITdzHFYNM9z_ehT3Gi_II9G-yY6eUhnrAfny-uz79Wl9-_fDs_u6xIoJ6rfoBOCEmoNbmh6VEMddvXUItG2raUndJSw1opaJpOKrVGqdxaO1Drru6kOGHvHvZuUvy5UJ7N5LOjcbSB4pKNqmXTaIUFfPMfeBeXFMptphYgZFu3TYFeH6BlPVFvNslP5S3zT9MCvD0ARUM7Dqmo6_Mjp5WUYkedPlBUPt96Sia7Iqaj3idys-mjNwhm57XZe212RhoAs_fatOIvUqaauA</recordid><startdate>20001228</startdate><enddate>20001228</enddate><creator>Boden, William E</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20001228</creationdate><title>Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes</title><author>Boden, William E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e318t-df09335e188ecf4d13f26d202345a6d13978580b770449577b157cb8c07b92953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Angina pectoris</topic><topic>Angina, Unstable - drug therapy</topic><topic>Angina, Unstable - mortality</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Cardiology</topic><topic>Clinical outcomes</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Assessment</topic><topic>Survival Analysis</topic><topic>Syndrome</topic><topic>Therapy</topic><topic>Thrombolytic Therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boden, William E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boden, William E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2000-12-28</date><risdate>2000</risdate><volume>86</volume><issue>12</issue><spage>42</spage><epage>47</epage><pages>42-47</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-driven process. An early routine invasive or “drive-through” strategy, which consists of cardiac catheterization followed by percutaneous coronary intervention within 24 hours of the onset of angina, has not been shown to result in improved outcomes. In fact, investigators in the Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) trial found that aggressively treated patients had significantly worse outcomes during the first year of follow-up than did those treated with a conservative strategy. In this overview, a conservative (ischemia-guided) strategy with aggressive medical therapy is recommended for patients with non–ST-segment elevation acute coronary syndrome. This conservative treatment includes intensive antiplatelet, antithrombotic, and anti-ischemic therapy combined with careful clinical assessment and provocative testing. Patients undergo catheterization and revascularization only if spontaneous angina occurs or there is objective evidence of stress-induced myocardial ischemia. In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk. Tailoring therapy to the level of risk is essential to optimizing efficacy and clinical outcomes.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11206018</pmid><doi>10.1016/S0002-9149(00)01480-6</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9149
ispartof The American journal of cardiology, 2000-12, Vol.86 (12), p.42-47
issn 0002-9149
1879-1913
language eng
recordid cdi_proquest_miscellaneous_72544871
source MEDLINE; Elsevier ScienceDirect Journals
subjects Angina pectoris
Angina, Unstable - drug therapy
Angina, Unstable - mortality
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Cardiology
Clinical outcomes
Health risk assessment
Humans
Medical sciences
Myocardial Infarction - drug therapy
Myocardial Infarction - mortality
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Risk Assessment
Survival Analysis
Syndrome
Therapy
Thrombolytic Therapy
Treatment Outcome
title Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A28%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Avoidance%20of%20routine%20revascularization%20in%20the%20management%20of%20patients%20with%20non-ST-segment%20elevation%20acute%20coronary%20syndromes&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Boden,%20William%20E&rft.date=2000-12-28&rft.volume=86&rft.issue=12&rft.spage=42&rft.epage=47&rft.pages=42-47&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/S0002-9149(00)01480-6&rft_dat=%3Cproquest_pubme%3E72544871%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230356264&rft_id=info:pmid/11206018&rft_els_id=S0002914900014806&rfr_iscdi=true